Literature DB >> 15911796

Association between family history of dementia and hallucinations in Parkinson disease.

Diana Paleacu1, Edna Schechtman, Rivka Inzelberg.   

Abstract

OBJECTIVE: To identify familial risk factors for hallucinations in patients with Parkinson disease (PD).
METHODS: Two hundred seventy-six outpatients with PD participated in the study. The presence of hallucinations was determined using a validated questionnaire, including items regarding the occurrence of visual, auditory, or other types of hallucinations. Family history of PD and dementia was determined by a structured interview and examination of medical records and affected family members. Patients with young-onset PD (<50 years) who reported another PD patient among their siblings were tested for parkin mutations. Stepwise logistic regression was applied for the detection of risk factors. The regression model included a set of family history-related variables (family history of PD and of dementia) and a set of disease-related variables (age, age at onset of PD, stage, duration of PD and of l-dopa therapy, l-dopa dose, and number of antiparkinsonian drugs).
RESULTS: Hallucinations were present in 32% of the 276 patients. Risk factors for hallucinations included Mini-Mental State Examination score (p < 0.0001) and positive family history of dementia (p = 0.0005).
CONCLUSION: Family history of dementia and lower Mini-Mental State Examination scores are risk factors for hallucinations in Parkinson disease.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15911796     DOI: 10.1212/01.WNL.0000161872.85903.8E

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  9 in total

1.  Prevalence of psychotic symptoms in a community-based Parkinson disease sample.

Authors:  Joel Mack; Peter Rabins; Karen Anderson; Susanne Goldstein; Stephen Grill; Elaina S Hirsch; Susan Lehmann; John T Little; Russell L Margolis; Justin Palanci; Gregory Pontone; Howard Weiss; James R Williams; Laura Marsh
Journal:  Am J Geriatr Psychiatry       Date:  2012-02       Impact factor: 4.105

Review 2.  [Parkinson's disease and psychoses].

Authors:  Jacopo Vittoriano Bizzarri; Giancarlo Giupponi; Ignazio Maniscalco; Patrizia Schroffenegger; Andreas Conca; Hans Peter Kapfhammer
Journal:  Neuropsychiatr       Date:  2015-01-14

3.  Incidence, Prevalence, and Mortality of Psychosis Associated with Parkinson's Disease (1991-2010).

Authors:  Cole D Stang; Aidan F Mullan; Emanuele Camerucci; Mania Hajeb; Pierpaolo Turcano; Peter Martin; Michelle M Mielke; Keith A Josephs; Matthew Splett; Victor Abler; Bradley F Boeve; James H Bower; Rodolfo Savica
Journal:  J Parkinsons Dis       Date:  2022       Impact factor: 5.520

Review 4.  Pathophysiology and treatment of psychosis in Parkinson's disease: a review.

Authors:  Laura B Zahodne; Hubert H Fernandez
Journal:  Drugs Aging       Date:  2008       Impact factor: 3.923

Review 5.  Psychosis in Parkinson's Disease: Epidemiology, Pathophysiology, and Management.

Authors:  Anna Chang; Susan H Fox
Journal:  Drugs       Date:  2016-07       Impact factor: 9.546

6.  Calpastatin gene (CAST) is not associated with late onset sporadic Parkinson's disease in the Han Chinese population.

Authors:  Lan Zhang; Hui Ding; Dan-Hui Wang; Yan-Li Zhang; Andrius Baskys; Piu Chan; Yu Zhong; Yan-Ning Cai
Journal:  PLoS One       Date:  2013-08-09       Impact factor: 3.240

7.  A clinical profile of patients with Parkinson's disease and psychosis.

Authors:  B R Amar; Ravi Yadav; Y C Janardhan Reddy; Pramod Kumar Pal
Journal:  Ann Indian Acad Neurol       Date:  2014-04       Impact factor: 1.383

Review 8.  Psychiatric aspects of Parkinson's disease.

Authors:  Sandeep Grover; Mansi Somaiya; Santhosh Kumar; Ajit Avasthi
Journal:  J Neurosci Rural Pract       Date:  2015-01

9.  Auditory and visual hallucination prevalence in Parkinson's disease and dementia with Lewy bodies: a systematic review and meta-analysis.

Authors:  Charlotte Louise Eversfield; Llwyd David Orton
Journal:  Psychol Med       Date:  2018-11-26       Impact factor: 7.723

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.